Contact Information: Delcath Systems, Inc. Contact: Mr. Richard Taney President & Chief Executive Officer T: (212) 489-2100 E: Investor Relations Contact: Mr. Richard Cooper Chairman Mr. Cass Almendral Vice President Strategic Growth International, Inc. T: 212-838-1444 E:
Delcath Systems' Targeted Drug Delivery System for Liver Cancer Treatment to Be Featured on FOX Business News
Program to Discuss Trend Towards Regionalized Treatment of Cancer
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - July 15, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ) today
announced that CEO Richard L. Taney will appear on FOX Business Network
(FBN) to discuss the Company's proprietary Percutaneous Hepatic Perfusion
(PHP) System, which is designed to deliver targeted high doses of
therapeutic and chemotherapeutic agents. The PHP System is currently being
tested in Phase III and II clinical trials for the treatment of
hepatocellular carcinoma and metastatic tumors in the liver. Also appearing
on this segment will be Dr. James Pingpank of the National Cancer Institute
in Bethesda, Maryland. Dr. Pingpank is the Principal Investigator for the
Company's ongoing pivotal Phase III trial of metastatic melanoma in the
liver. Mr. Taney will discuss the health industry's efforts towards
treating cancer on a regionalized basis and provide an update on current
approaches to the treatment of liver cancer, including Delcath's PHP
System. Mr. Taney will be featured on the "Money for Breakfast" segment on
Wednesday, July 16, 2008 to be broadcast at 7:30 AM/ET.
In making this announcement, Mr. Taney commented, "The appearance on FOX
Business News is an important step in our ongoing effort to increase public
awareness of the Company's targeted drug delivery system for the treatment
of liver cancers. We are pleased to have the opportunity to present our
technology and the promise that it holds for patients suffering from this
terrible disease."
FOX Business Network (FBN) is a financial news channel delivering real-time
information across all platforms that impact both Main Street and Wall
Street. FBN is headquartered in New York, the business capital of the
world. Launched in October 2007, the Network is available in more than 35
million homes in major markets across the United States. Owned by News
Corp., the Network has bureaus in Chicago, Los Angeles, Silicon Valley,
Washington, DC and London. (www.foxbusiness.com).
About Delcath Systems, Inc.
Delcath Systems is a technology-based therapeutic company specializing in
cancer treatment. The Company is working to complete its first Phase III
clinical trial for its Percutaneous Hepatic Perfusion System ("PHP") for
the isolated delivery of high doses of therapeutic and chemotherapeutic
agents. The PHP System is currently being tested in Phase III and Phase II
clinical trials for the treatment of hepatocellular carcinoma and
metastatic tumors in the liver, including melanomas, neuroendocrine tumors
and adenocarcinomas. The Company's intellectual property portfolio
currently consists of twenty-eight patents on a worldwide basis including
the U.S., Europe, Asia and Canada. For more information, please visit the
Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.